SCHEMBL23326235

SCHEMBL23326235

Cc1nc2nc(Nc3ccccc3)cnc2cc1NC(=O)Nc1ccc(F)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 4/20 0.54
▸ MEN1 O00255 5/20 0.48
▸ KMT2A Q03164 5/20 0.48
▸ MAPT P10636 5/20 0.48
▸ LMNA P02545 4/20 0.47
▸ HTT P42858 3/20 0.47
▸ TP53 P04637 1/20 0.47
▸ NPC1 O15118 3/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ IDH1 O75874 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ MAPK8 P45983 3/20 0.44
▸ MAPK9 P45984 3/20 0.44
▸ MAPK10 P53779 3/20 0.44
▸ CSNK1A1 P48729 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ SLC2A1 P11166 1/20 0.44
▸ KDR P35968 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20595298 0.93 PIK3CA (0.46) PIK3CAMEN1KMT2AMAPTLMNA
SCHEMBL20595308 0.92 MEN1 (0.48) PIK3CAMEN1KMT2AMAPTLMNA
SCHEMBL20595309 0.91 MEN1 (0.49) PIK3CAMEN1KMT2AMAPTLMNA
SCHEMBL23344475 0.87 PIK3CA (0.52) PIK3CAMAPK8MAPK9MAPK10KDR
SCHEMBL23344453 0.87 PIK3CA (0.68) PIK3CAMEN1KMT2AMAPTNPC1
SCHEMBL23326195 0.87 MEN1 (0.51) PIK3CAMEN1KMT2AMAPTLMNA
SCHEMBL23344450 0.87 KCNQ3 (0.45) PIK3CANPC1RAB9ASMN1; SMN2MAPK8
SCHEMBL23344437 0.86 PIK3CA (0.47) PIK3CAMEN1KMT2AMAPTLMNA
SCHEMBL23326267 0.86 PIK3CA (0.56) PIK3CAMEN1KMT2AMAPTLMNA
SCHEMBL23344439 0.84 PIK3CA (0.76) PIK3CAMEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11117894-B2 Pyridopyrazine compounds and uses thereof CITY OF HOPE (US) 2021-09-14 — — US disclosed
US-11117894-B2 Pyridopyrazine compounds and uses thereof CITY OF HOPE (US) 2021-09-14 — — US disclosed
US-20210139476-A1 PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (GR) 2021-05-13 — — US disclosed
US-20210139476-A1 PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (GR) 2021-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11117894-B2 Pyridopyrazine compounds and uses thereof PDXK, DPYD, PNPO PIK3CA 1262/4885MEN1 4106/4885KMT2A 2474/4885
US-20210139476-A1 PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF PDXK, DPYD, PNPO PIK3CA 1262/4885MEN1 4106/4885KMT2A 2474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback